

# **Alexa Sengupta**

## **Associate**

Nashville +1.615.780.6768

Alexa.Sengupta@klgates.com

#### **OVERVIEW**

Alexa Sengupta is an associate at the firm's Nashville office. She is a member of the Health Care and FDA practice group.

She focuses her practice on both health care and FDA regulatory matters, advising clients on requirements related to medical devices, pharmaceuticals, and biologics, as well as cosmetics and dietary supplements.

Alexa also has experience assisting with federal and state healthcare regulatory and compliance matters, including: fraud and abuse concerns relating to the Stark law, Anti-kickback Statute, and False Claims Act; Medicare enrollment-related issues; and health care state licensure and day-to-day operational issues.

Alexa also assists in the execution of corporate transactions, particularly focusing on health care clients, by advising clients through mergers and acquisitions, strategic collaborations, and joint ventures.

#### PROFESSIONAL BACKGROUND

Prior to joining the firm, Alexa served as a corporate health care associate at a U.S. law firm, where she counseled organizations regarding health care regulatory compliance and operational matters and assisted in corporate transactions.

#### **EDUCATION**

- J.D., University of Tennessee College of Law, 2019 (Tennessee Law Review)
- B.A., Middle Tennessee State University, 2014

# THOUGHT LEADERSHIP POWERED BY HUB

- 12 October 2023, FDA Issues Guidance on Informed Consent for IRBs, Clinical Investigators, and Sponsors
- 28 June 2023, Litigation Minute: FDA and State Action on PFAS in Food Packaging
- 9 March 2023, MSSP vs ACO REACH: Five Considerations for Legal Counsel

# K&L GATES

- 5 January 2023, Breakthrough FDA Decision: Agency Completes its First Pre-Market Consultation for Human Food Made From Cultured Animal Cells
- 18 October 2022, FDA Proposes Updates Regulatory Definition of "Healthy" for the First Time Since 1994
- 7 June 2022, The Drive to Align ESG and Health Equity Priorities With Medicare Reimbursement Models
- 16 March 2022, The Next Evolution of ACO Models Applications for the ACO REACH Model Are Due 22 April 2022

## **AREAS OF FOCUS**

Health Care and FDA